Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Applied DNA Sciences (NASDAQ:APDN) has announced it will release its first quarter fiscal 2025 financial results after market close on Thursday, February 13, 2025. The company will host a conference call and webcast for shareholders and investors at 4:30 p.m. ET on the same day.
The conference call will be accessible via multiple channels including domestic toll-free, international, and Canadian toll-free numbers. A live webcast will be available, and an accompanying slide presentation will be embedded in both live and replay formats. A replay of the conference call will be available for 7 days following the event through various access numbers with the replay access code 7896562.
Applied DNA Sciences (NASDAQ:APDN) ha annunciato che pubblicherà i suoi risultati finanziari per il primo trimestre dell'esercizio fiscale 2025 dopo la chiusura del mercato giovedì 13 febbraio 2025. L'azienda ospiterà una conferenza telefonica e un webcast per azionisti e investitori alle 16:30 ET dello stesso giorno.
La conferenza telefonica sarà accessibile tramite diversi canali, inclusi numeri verdi nazionali, internazionali e numeri verdi canadesi. Un webcast in diretta sarà disponibile e una presentazione in formato slide sarà incorporata sia nel formato dal vivo che nel replay. Una registrazione della conferenza telefonica sarà disponibile per 7 giorni dopo l'evento tramite vari numeri di accesso con il codice di accesso per il replay 7896562.
Applied DNA Sciences (NASDAQ:APDN) ha anunciado que publicará sus resultados financieros del primer trimestre del ejercicio fiscal 2025 después del cierre del mercado el jueves 13 de febrero de 2025. La compañía realizará una conferencia telefónica y un webcast para accionistas e inversores a las 4:30 p.m. ET el mismo día.
La conferencia telefónica será accesible a través de múltiples canales, incluidos números gratuitos nacionales, internacionales y números gratuitos canadienses. Habrá un webcast en vivo disponible y una presentación de diapositivas adjunta se incorporará tanto en formatos en vivo como en repetición. Una repetición de la conferencia telefónica estará disponible durante 7 días después del evento a través de varios números de acceso con el código de acceso para la repetición 7896562.
Applied DNA Sciences (NASDAQ:APDN)는 2025 회계연도 1분기 재무 결과를 2025년 2월 13일 목요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 주주 및 투자자를 위한 컨퍼런스 콜 및 웹캐스트를 개최합니다.
컨퍼런스 콜은 국내 무료 전화, 국제 전화, 캐나다 무료 전화 번호 등 여러 경로를 통해 접근 가능합니다. 라이브 웹캐스트가 제공되며, 슬라이드 프레젠테이션이 라이브 및 재생 형식 모두에 삽입됩니다. 컨퍼런스 콜의 재생은 이벤트 후 7일 동안 다양한 접근 번호와 재생 접근 코드 7896562를 통해 이용할 수 있습니다.
Applied DNA Sciences (NASDAQ:APDN) a annoncé qu'elle publiera ses résultats financiers du premier trimestre de l'exercice fiscal 2025 après la clôture du marché le jeudi 13 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire pour les actionnaires et les investisseurs à 16h30 ET le même jour.
La conférence téléphonique sera accessible par plusieurs canaux, y compris des numéros gratuits nationaux, internationaux et canadiens. Un webinaire en direct sera disponible, et une présentation en diaporama sera intégrée à la fois en format live et en replay. Un replay de la conférence téléphonique sera disponible pendant 7 jours après l'événement via divers numéros d'accès avec le code d'accès au replay 7896562.
Applied DNA Sciences (NASDAQ:APDN) hat angekündigt, dass es seine Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 nach Börsenschluss am Donnerstag, den 13. Februar 2025, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast für Aktionäre und Investoren abhalten.
Die Telefonkonferenz wird über mehrere Kanäle zugänglich sein, darunter nationale gebührenfreie Nummern, internationale und kanadische gebührenfreie Nummern. Ein Live-Webcast wird verfügbar sein, und eine begleitende Präsentation wird sowohl in Live- als auch in Wiederholungsformaten eingebettet sein. Eine Wiederholung der Telefonkonferenz wird 7 Tage nach der Veranstaltung über verschiedene Zugangsnummern mit dem Wiederholungszugangscode 7896562 verfügbar sein.
- None.
- None.
Investor Call and Webcast Scheduled for 4:30 P.M ET
STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025.
The Company will host a conference call for shareholders and the investment community at 4:30 p.m. ET on that same day.
Webcast and Conference Call Date & Time: Thursday, February 13 @ 4:30 p.m. ET
Dial In:
Domestic callers (toll free): 844-887-9402
International callers: 412-317-6798
Canadian callers (toll free): 866-605-3852
Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=3UkskFxG
A replay of the conference call will be available for 7 days following the conclusion of the call:
Replay for domestic callers (toll free): 877-344-7529, replay access code 7896562
Replay for international callers: 412-317-0088, replay access code 7896562
Replay for Canadian callers (toll free): 855-669-9658, replace access code 7896562
An accompanying slide presentation will be embedded in the webcast (live and replay) that can also be accessed via the ‘Company Presentations' page of the Applied DNA investor relations website (https://investors.adnas.com/corporate-profile/company-presentation/). The webcast replay of the call will be available approximately one hour after the end of the call on the ‘Company Events' page (https://investors.adnas.com/news-events/company-events/).
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
For additional information:
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web: https://investors.adnas.com/
SOURCE: Applied DNA Sciences
View the original press release on ACCESS Newswire
FAQ
When will Applied DNA (APDN) release its Q1 2025 earnings?
What time is Applied DNA's (APDN) Q1 2025 earnings call?
How can investors access Applied DNA's (APDN) Q1 2025 earnings call?
How long will Applied DNA's (APDN) Q1 2025 earnings call replay be available?
